FEC mobilized stem cells for high-dose therapy in breast cancer patients

Acta Oncologica

Volumn 38, Issue 2, 1999, Pages 239-245

  Lindman, Henrik ^a   Wiklund, Tom ^b   Holte, Harald ^c   Ljungman, Per ^d   Blomqvist, Carl ^b   Kvalheim, Gunnar ^c   Bengtsson, Mats ^a   Höglund, Martin ^a   Wilking, Nils ^d   Bergh, Jonas ^a,d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL MOTILITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HUMAN; MAJOR CLINICAL STUDY; NEUTROPHIL; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE; TREATMENT OUTCOME;

EID: 0032903487     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699431672     Document Type: Article

References (30)

1. 1. Antman K, Rowlings P, Vaughan W, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
2. 2. Elias A, Ayash L, Anderson K, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-44.
3. 3. Gianni A, Gregni M, Siena S, et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol Oncol 1989; 7: 139-48.
4. 4. Jones H, Jones S, Watts M, et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693-702.
5. 5. Schmitz N, Linch D, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-7.
6. 6. Peters W, Shpall E, Jones R, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-76.
7. 7. Dunphy F, Spitzer G, Buzdar A, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-16.
8. 8. Kennedy M, Beveridge R, Rowley S, Gordon G, Abeloff M, Davidson N. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-6.
9. 9. Williams S, Gilewski T, Mick R, Bitran J. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-7.
10. 10. Antman K, Souhami R. High-dose chemotherapy in solid tumours. Annals Oncol 1993; 4: 29-44.
11. 11. Ayash L, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
12. 12. Leonard R. High-dose chemotherapy for breast cancer. Eur J Cancer 1996; 32A; 205-8.
13. 13. Bezwoda W, Seymour L, Dansey R. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-9.
14. 14. Gianni A, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; II: 580-5.
15. 15. Gianni A, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768-78.
16. 16. Bregni M, Siena S, Di Nicola M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 1996; 14: 628-35.
17. 17. Kotasek D, Shepherd K, Sage R, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transpl 1992; 9: 11-7.
18. 18. Sheridan W, Begley C, Juttner C, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4.
19. 19. Eder J, Elias A, Shea T, et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239-45.
20. 20. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-10.
21. 21. Bergh J, Wiklund T, Erikstein B, et al. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity to high-risk breast cancer patients. Ann Oncol 1998; 9: 403-11.
22. 22. Schwartzberg L, Birch R, Blanco R, et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transpl 1993; 11: 369-74.
23. 23. Colton T. Statistics in medicine. Boston: Little, Brown, 1974.
24. 24. Brugger W, Bross K, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-40.
25. 25. EBCTCG. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
26. 2 in patients with advanced cancer. Aust NZ J Med 1992; 22: 660-4.
27. 27. Rosenfeld C, Shadduck R, Zeigler Z, Andrews F, Nemunaitis J. Cyclophosphamide-mobilized peripheral blood stem cells in patient with lymphoid malignancies. Bone Marrow Transpl 1995; 15: 433-8.
28. 28. Watts M, Sullivan A, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535-46.
29. 29. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and aulografling of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-94.
30. 30. Zimmerman T, Lee W, Bender J, Mick R, Williams S, et al. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transpl 1995; 15: 439-44.